DRESS Syndrome Following Levofloxacin Exposure With Positive Patch-test

Charfi, Ons; Lakhoua, Ghozlane; Sahnoun, R.; Badri, Talel; Daghfous, Riadh; Aidli, Sihem El; Kastalli, Sarrah; Zaiem, Ahmed

doi:10.2515/therapie/2015046

Cited by 13 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levofloxacin has been reported to cause toxic epidermal necrolysis (TEN) and Stevens‐Johnson syndrome (SJS) . To the best of our knowledge, only three cases of DRESS/DIHS have been reported to date . DRESS/DIHS is characterized by reactivation of HHV‐6, which does not occur in TEN/SJS .…”

Section: Discussionmentioning

confidence: 99%

Drug reaction with eosinophilia and systemic symptoms/drug‐induced hypersensitivity syndrome (DRESS/DIHS) caused by levofloxacin in a patient with systemic scleroderma, rheumatoid arthritis, and Sjogren syndrome

et al. 2018

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Drug reaction with eosinophilia and systemic symptoms/drug‐induced hypersensitivity syndrome (DRESS/DIHS) caused by levofloxacin in a patient with systemic scleroderma, rheumatoid arthritis, and Sjogren syndrome

et al. 2018

View full text Add to dashboard Cite

“…Patch testing involves the application of an implicated and/or potentially cross‐reactive drug with a control vehicle (petroleum jelly) to the skin for 48 h, which is subsequently read after 48–96 h and if possible 7 days. The safety of patch testing in SCARs has been increasingly demonstrated . Systemic (but nonlife‐threatening) reactions have been reported infrequently with patch testing, although mostly for antituberculosis drugs in patients with HIV .…”

Section: Causality Assessment Through Clinical In Vivo and Ex Vivo Tmentioning

confidence: 99%

Recent advances in the understanding of severe cutaneous adverse reactions

et al. 2017

View full text Add to dashboard Cite

Severe cutaneous adverse reactions (SCARs) encompass a heterogeneous group of delayed hypersensitivity reactions, which are most frequently caused by drugs. Our understanding of several aspects of SCAR syndromes has evolved considerably over the previous decade. This review explores evolving knowledge on the immunopathogenic mechanisms, pharmacogenomic associations, in-vivo and ex-vivo diagnostics for causality assessment and medication cross-reactivity data related to SCAR syndromes. Given the rarity and severity of these diseases, multidisciplinary collaboration through large international, national and/or multicentre networks to collect prospective data on patients with SCAR syndromes should be prioritized. This will further enhance a systematised framework for translating epidemiological, clinical, and immunopathogenetic advances into preventive efforts and improved outcomes for patients.

show abstract

“…Algunos estudios han implementado la prueba de parche como herramienta para la búsqueda del medicamento implicado en el desarrollo del DRESS [71,72]; sin embargo, no hay consenso sobre su utilización. Para esta prueba la sustancia en cuestión se pone en contacto con la piel y se observa posteriormente la reacción inflamación cutánea (véase figura 4) [73].…”

Section: Prueba De Parcheunclassified

Reacciones adversas cutáneas severas a medicamentos: estado del conocimiento

Villa-Arango¹,

Acevedo-Vásquez²,

Cardona-Villa³

2016

Med. Lab.

View full text Add to dashboard Cite

Las reacciones adversas a medicamentos afectan de manera global entre el 10% y el 20% de los pacientes hospitalizados y el 7% de los pacientes ambulatorios. Aproximadamente, uno de cada mil pacientes hospitalizados sufren reacciones adversas que amenazan la vida. Las reacciones adversas a medicamentos, denominadas como reacciones alérgicas (inmunológicas), se pueden agrupar según la clasificación de Gell y Coombs en: tipo I (mediada por IgE), tipo II (citotóxica), tipo III (por inmunocomplejos) y tipo IV (hipersensibilidad retardada o celular). Actualmente, las reacciones tipo IV se subclasifican según la célula efectora involucrada y sus correspondientes citoquinas. Estos subgrupos se definen como: tipo IVa (con activación del perfil Th1, los macrófagos como células efectoras y liberación de INF-γ y TNF-α), tipo IVb (con activación del perfil Th2, los eosinófilos como células efectoras y liberación de citoquinas como la IL-5, la IL-4 y la IL-13), tipo IVc (con los linfocitos T citotóxicos como células efectoras y liberación de granzimas B y perforinas) y tipo IVd (con los neutrófilos como células efectoras y liberación de CXCL8 y factor estimulante de colonias de granulocitos y macrófagos). La presente revisión se centra en la epidemiología, etiología, fisiopatología y manifestaciones clínicas de las reacciones adversas cutáneas severas a medicamentos como el síndrome de Stevens Johnson, la necrólisis epidérmica tóxica, el síndrome DRESS y la pustulosis exantemática generalizada aguda (PEGA); además de un abordaje terapéutico en cada una de estas enfermedades.

show abstract

DRESS Syndrome Following Levofloxacin Exposure With Positive Patch-test

Cited by 13 publications

References 8 publications

Drug reaction with eosinophilia and systemic symptoms/drug‐induced hypersensitivity syndrome (DRESS/DIHS) caused by levofloxacin in a patient with systemic scleroderma, rheumatoid arthritis, and Sjogren syndrome

Drug reaction with eosinophilia and systemic symptoms/drug‐induced hypersensitivity syndrome (DRESS/DIHS) caused by levofloxacin in a patient with systemic scleroderma, rheumatoid arthritis, and Sjogren syndrome

Recent advances in the understanding of severe cutaneous adverse reactions

Reacciones adversas cutáneas severas a medicamentos: estado del conocimiento

Contact Info

Product

Resources

About